Sydney Shareholder Information Session July 2018

Kazia Therapeutics hosted briefing sessions for shareholders in Sydney and Melbourne this month.

Kazia’s CEO Dr James Garner gave an overview of the company’s achievements over the past year, including recent out-licensing agreements and an update on the current clinical trials of the company’s therapies Cantrixil (for recurrent ovarian cancer) and GDC-0084 (for the brain cancer glioblastoma multiforme).